Buffalo, NY (PRWEB) February 03, 2016 -- ZeptoMetrix™ Corporation (ZMC), announced today the release of several new products to aid in the rapid development and ongoing quality control of molecular assays targeting the Zika Virus.
“Our level of concern with the Zika Virus outbreak is extremely high,” Dr. Gregory R. Chiklis, President and CEO of ZeptoMetrix, relayed to his Executive Team. “We need to support the molecular diagnostic industry with accurate, reliable and non-infectious tools to alleviate the level of uncertainty that exists. These molecular based assays are without a doubt the most sensitive and specific ways to identify and monitor a Zika Virus infection.”
To complement its current Tropical Disease microorganism offerings, ZeptoMetrix has added 3 strains of Zika Virus for the development and verification of molecular diagnostic assays. These strains can be used to optimize test sensitivity. Other arboviruses from the ZeptoMetrix collection, such as Dengue Virus, Yellow Fever, and Chikungunya can be used to test that an assay is specific for the Zika Virus.
For clinical laboratory use, ZeptoMetrix has treated Zika Virus with its proprietary NATtrol™ inactivation process to manufacture non-infectious, molecular testing controls and an assay range validation panel. Together, these quality controls products can be utilized to verify test performance, track variations in results, follow lot-to-lot test kit reproducibility, monitor individual operator performance and determine aberrant long-term trends in laboratory results.
ZeptoMetrix Corporation (ZMC) is a renowned industry leader and innovator identified with quality, reliable and trusted products and services for infectious disease diagnostic development. ZeptoMetrix is a fully integrated biotechnology company whose offerings support all phases of research & development, validation, manufacturing and commercialization of diagnostic testing.
Founded in 1999, ZeptoMetrix is headquartered in Buffalo, NY with additional facilities in Franklin, Massachusetts.
Globally, millions of people are tested for infectious diseases annually. The implications of reporting either a false positive or a false negative can be devastating to the patient. Accurate and sensitive diagnostics are necessary to confirm that laboratories are providing patients with proper testing results.
Utilizing ZeptoMetrix™ NATtrol™ External Run Controls on a consistent basis helps to monitor testing performance to maximize additional confidence in a patient’s reported results.
ZeptoMetrix NATtrol Molecular Diagnostic Products are an essential part of today’s fast growing market and are designed provide the safest, most accurate and cost effective support for critical microorganism detection.
The ZeptoMetrix NATtrol treatment blocks surface protein receptors on highly purified microorganisms rendering them non-infectious while allowing the internal nucleic acids to remain intact for molecular detection.
Mimicking a true, infected clinical specimen, these ready-to-use non-infectious products are safe to use and refrigerator stable while controlling for all steps in molecular testing including: centrifugation, extraction, amplification and nucleic acid detection.
The routine and repetitive use of NATtrol External Run Controls enables laboratories to:
• Train and Monitor Laboratory Personnel
• Evaluate Lot-to-Lot Consistency of Test Kit and Assay Reagents
• Monitor Daily Variations in Reported Results
• Provide Unbiased Test Reproducibility
• Assist in the CLIA Required Verification of Diagnostic Tests
• Provide Consistent, Reliable and Accurate Quality Control Solutions
• Assist in Identifying Laboratory Trends
For Sales and/or information regarding Zika Virus Products as well as other ZeptoMetrix Product Lines, please contact ZeptoMetrix Customer Relations directly.
ZeptoMetrix Corporation, Customer Relations
878 Main Street
Buffalo, NY 14202
Michael Hershfield, Vice President, Sales & Marketing
SOURCE [email protected]